Evaluation of an EMR-Based Clinical Decision Support Tool for the Implementation of Guideline-Directed Therapies for Prevention of Heart Failure Among High-Risk Patients With Type 2 Diabetes

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable

Type 2 diabetes mellitus (T2DM) is an independent risk factor for heart failure (HF) and is associated with significant morbidity and mortality. Recent therapeutic advances in pharmacotherapies, such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown to be beneficial in preventing HF among patients with T2DM. However, despite widely available risk prediction and stratification tools and evidence-based practice guidelines, SGLT-2i medications are under-prescribed in the United States. The proposed study is a pragmatic, single-center, randomized trial to test the feasibility and effectiveness of a clinical decision support (CDS) tool to alert providers and improve HF risk stratification in patients with T2DM.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• Providers in a General Internal Medicine outpatient clinic encounter

• Providers in a subspecialty Internal Medicine outpatient clinic encounter

• Providers in family medicine outpatient clinic encounter

United States
University of Texas Southwestern Medical Center
Contact Information
Ambarish Pandey, MD, MSCS
Time Frame
Start Date: March 25, 2021
Estimated Completion Date: October 2022
Target number of participants: 1500
Experimental: Electronic Alert
Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of HF in diabetes and the lack of an active order for SGLT2i therapy.
No Intervention: No Alert
The CDS will not issue an on-screen alert.
Leads: University of Texas Southwestern Medical Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials